NCT05050630 is a Phase 2 clinical trial of TR2-ICE in Age Range ≥16 Years, Gender Unlimited, sponsored by Affiliated Hospital to Academy of Military Medical Sciences.

Who is sponsoring NCT05050630?

NCT05050630 is sponsored by Affiliated Hospital to Academy of Military Medical Sciences.

What drugs are being tested in NCT05050630?

Interventions in NCT05050630: TR2-ICE.

What condition does NCT05050630 study?

NCT05050630 studies Age Range ≥16 Years, Gender Unlimited, Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma, Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed, At Least One Positive Lesion According to the 2014 Lugano Criteria for Hodgkin's and Non-Hodgkin's Lymphoma, ECOG Physical Status Score is 0-3, The Researchers Judged That Life Expectancy Was at Least Three Months, Understand and Voluntarily Sign Written Informed Consent.

Is NCT05050630 still recruiting?

NCT05050630 is currently status unknown. Last updated 20 September 2021.

Last reviewed 2021-09-20 · How we verify

NCT05050630

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL

Status unknown Phase 2 Last updated 20 September 2021

What this trial tests

Phase 2 trial testing TR2-ICE in Age Range ≥16 Years, Gender Unlimited in 73 participants. Status unknown.

Timeline

1 August 2021

Primary endpoint
30 July 2022

30 July 2023

Quick facts

Lead sponsor	Affiliated Hospital to Academy of Military Medical Sciences
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	73
Start date	1 August 2021
Primary completion	30 July 2022
Estimated completion	30 July 2023
Sites	1 location across China

Drugs / interventions tested

TR2-ICE — full drug profile →

Conditions studied

Age Range ≥16 Years, Gender Unlimited — all drugs for Age Range ≥16 Years, Gender Unlimited →
Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma — all drugs for Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma →
Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed — all drugs for Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed →
At Least One Positive Lesion According to the 2014 Lugano Criteria for Hodgkin's and Non-Hodgkin's Lymphoma — all drugs for At Least One Positive Lesion According to the 2014 Lugano Criteria for Hodgkin's and Non-Hodgkin's Lymphoma →

Sponsor

Affiliated Hospital to Academy of Military Medical Sciences

Who can join

16 and older, any sex, with Age Range ≥16 Years, Gender Unlimited or Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was a prospective, multi-center, single-arm, Phase II clinical study. Compared with the literature data, objective response rate (ORR) and complete response rate (CR) were the primary endpoint, and 1-year and 2-year progression-free survival (PFS) and 2-year overall survival (OS) were the secondary endpoint. To evaluate the efficacy and safety of TR2-ICE sequential Tirelarizin, lenalidomide alone, or both maintenance therapy in the rescue of patients with relapsed and refractory diffuse large B or high-grade B-cell lymphoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Affiliated Hospital to Academy of Military Medical Sciences trials

Trials by the same sponsor.

NCT06986434 — CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differenti · EARLY_PHASE1 · not yet recruiting
NCT07416682 — CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms · EARLY_PHASE1 · not yet recruiting
NCT06834529 — CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma · Phase 1, PHASE2 · recruiting
NCT06152263 — LCI in Chronic Atrophic Gastritis and Early Gastric Cancer · unknown
NCT05645601 — CAR-NK Targeted CD19 for r/r B-cell Malignancies · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05050630 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Affiliated Hospital to Academy of Military Medical Sciences
Last refreshed: 20 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05050630.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing